Computer-Aided Drug Design added to global fight against COVID-19

Cutting edge chemical science technology and computer-aided drug design (CADD) is bringing together leading minds from across the world to help tackle the COVID-19 crisis Life sciences company UCB is the first pharma company to join the COVID Moonshot crowdsourcing initiative, which involves the Diamond Light Source synchrotron facility in Oxfordshire and the Weizmann Institute of Science in Israel among others-encouraging anyone to submit designs to be synthesised and tested. Like many similar companies, UCB rapidly pivoted its business to lend its scientific expertise and experience to the cause, dedicating teams in its discovery research labs in Slough, UK and Braine-l'Alleud, Belgium along with the expertise of its team across the world, including its Medicinal Chemistry team, to produce a highly targeted drug that aims to counteract the viral replication element of the SARS-COV-2 virus. The data from the studies, successful or otherwise, is then made public and incorporated in the next design cycle until the most effective solutions are found.

Drug Designing: Open Access Journal is using Editorial Tracking System to maintain quality and transparency to the author in the peer-review process. Review processing will be performed by the editorial board members of the Journal Drug Designing: Open Access or by Reviewers (outside experts in the field). Two independent reviewer’s approval (Minimum reviewer’s approval) followed by editor approval is obligatory for acceptance of any manuscript excluding an editorial.

Journal is now accepting manuscripts for its upcoming issue Volume 9 Issue 4 and also for special issue on Role of Hydroxychloroquine and chloroquine in treatment of COVID 19. Special Issue aims to publish manuscripts explaining drug synthesis, trails, production, action on viral molecules, chemical formulation, treatment reports etc. Authors may submit original research article, review article, case studies, short commentary, systemic reviews, editorials etc.

Mail us at drugdesign@eclinicalsci.org if interested and for queries.

Editorial tracking submission: https://www.longdom.org/submissions/drug-designing-open-access.html

Nancy Ella
Editor Board
Drug Designing: Open Access
drugdesign@eclinicalsci.org